Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 622

1.

Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.

Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, Green D, Feinglass J, Trowbridge AA, Elliott CG.

Arch Intern Med. 1997 Feb 10;157(3):298-303.

PMID:
9040296
2.

A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.

Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, et al.

N Engl J Med. 1993 Nov 4;329(19):1370-6.

3.

Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.

Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J.

Ann Intern Med. 1993 Dec 1;119(11):1105-12.

PMID:
8239230
4.

Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.

Menzin J, Colditz GA, Regan MM, Richner RE, Oster G.

Arch Intern Med. 1995 Apr 10;155(7):757-64.

PMID:
7695464
5.

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.

Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, Trowbridge AA, Elliott CG, Green D, Feinglass J.

Arch Intern Med. 1997 Feb 10;157(3):289-94.

PMID:
9040295
7.
9.

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.

Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A.

Pharmacoeconomics. 2004;22(13):885-94.

PMID:
15329033
10.

Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.

O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, Gent M.

Arch Intern Med. 1999 Oct 25;159(19):2298-304.

PMID:
10547169
11.
12.
13.

Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.

Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G.

Am J Med. 2001 Aug;111(2):130-9.

PMID:
11498067
14.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
15.

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.

Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF.

Arch Intern Med. 2000 Jan 24;160(2):229-36.

PMID:
10647762
16.
17.
18.

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.

Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS.

Arch Intern Med. 1999 Jun 14;159(11):1221-8.

PMID:
10371230
19.

Supplemental Content

Support Center